Business
-
Almirall has licensed European rights to aclidinium bromide, both as a monotherapy and in combination with formoterol to Italian pharmaceutical company Menarini. The agreement covers most of the EU except for the UK, the Netherlands… Read more . . .
-
After spurning repeated offers from Valeant, ISTA Pharmaceuticals has agreed to be acquired by Bausch + Lomb for $9.10 per share in cash, a total of about $500 million. Valeant had offered $7.50 per share.… Read more . . .
-
A Massachusetts engineering firm called Enginasion has disclosed details of proprietary DPI-filling technology it says that it developed for a pharmaceutical client that needed accurate dispensing of a highly cohesive inhaled dry powder formulation into… Read more . . .
-
According to GlaxoSmithKline and Theravance, the two companies have now completed all studies for the Relovair fluticasone furoate (FF)/vilanterol (VI) DPI for both COPD and asthma, and they plan to move forward now with regulatory… Read more . . .
-
OINDP testing specialist NextBreath has successfully completed an evaluation by the World Health Organization (WHO) Performance Quality System (PQS) as a testing facility for nasal spray vaccine administration. The company is now accredited to perform… Read more . . .
-
Belgian biopharmaceutical company Ablynx has announced that Boehringer Ingelheim will extend funding for discovery, development, and commercialization of Ablynx’s Nanobody therapeutics for an additional two years, until September 2014. One of the Ablynx programs ALX-0171,… Read more . . .
-
Novartis has launched its once-daily Arcapta Neohaler indacaterol inhalation powder 75 mcg for the maintenance treatment of COPD in the US. The FDA approved the indacaterol product at the 75 mcg level in July 2011… Read more . . .
-
Belgian over the counter (OTC) specialist Omega Pharma has acquired several OTC products from GSK, including Beconase beclomethasone nasal spray. The deal, which also includes brands Lactacyd, Abtei, Solpadeine, Zantac, and Nytol totaled €470 million… Read more . . .
-
AstraZeneca has entered into a multi-year agreement with Galapagos subsidiaries BioFocus and Argenta to collaborate on discovery of compounds for the treatment of respiratory and inflammatory diseases. The deal allows AstraZeneca the use of Argenta’s… Read more . . .
-
Alexza Pharmaceuticals, whose lead product, Adasuve Staccato loxapine is under review by the FDA and the EMA, has reported a net loss of $40.5 million for the year ended December 31, 2011. The company also… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden